Clinical Stage Equipment
-
based in BELGIUM
CuraVac is a clinical-stage biotechnology company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines (or Active Targeted Immunotherapies) for autoimmune ...
-
Manufactured by Auro Vaccines LLCbased in USA
As part of its comprehensive Public Health and Biodefense vaccine franchise, under a license from the Henry M. Jackson Foundation, Auro Vaccines is developing a subunit vaccine (HeV-sG-V) composed of the envelope glycoprotein of Hendra virus for the prevention of Nipah virus (NiV) ...
-
Manufactured by Salutaris Medical Devices, Inc. (SMD)based in USA
SalutarisMD [SMD] is a clinical stage medical device company. SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV. The BetaCurve™ curves around the back of the eye to precisely deliver therapeutic beta radiation to the diseased area ...
-
based in USA
NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce local-regional hyperthermic temperatures in tumor tissue, intended to increase the ...
-
Manufactured by Auro Vaccines LLCbased in USA
Auro Vaccines has developed VesiculoVax™-vectored vaccines for pre- and post-exposure protection against the hemorrhagic disease caused by multiple species of filovirus (i.e. Zaire ebolavirus, Sudan ebolavirus and Marburg ...
-
Manufactured by Auro Vaccines LLCbased in USA
Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck ...
-
Manufactured by Elpisciencebased in CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...
-
Manufactured by Adrenomed AGbased in GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its ...
-
Manufactured by Femasys Inc.based in USA
FemBloc features our proprietary delivery platform, which places balloon technology close to the opening of both fallopian tubes. This in-office approach is designed to eliminate the risks of incisions, anesthesia, and hormones. As a nonsurgical procedure that is implant free, FemBloc delivers a biopolymer that is expected to expel within 3 months. Confirmation of procedure success can be ...
-
Manufactured by Synaffix BVbased in NETHERLANDS
GlycoConnect™ replaces the existing antibody glycan with a therapeutic payload. Synaffix has established a simple, yet powerful, clinical-stage platform technology enabling best-in-class ADCs, bispecific antibodies and the targeted delivery of various other therapeutic payloads, all without modifying the antibody ...
-
by STALICLAbased in SWITZERLAND
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to ...
-
by Verb Bioticsbased in USA
Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, ...
-
Manufactured by Navigo Proteins GmbHbased in GERMANY
Proteins’ Precision Capturing® technology dramatically simplifies non-Fc biologics downstream processing from pre-clinical stage to commercial manufacturing. This is achieved by substituting several chromatography steps by one single custom affinity chromatography capture step based on Navigo’s proprietary artificial Protein A ...
-
Manufactured by AVEO Pharmaceuticals, Inc.based in USA
AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, ...
-
Manufactured by AMS Biotechnology (Europe) Ltd.based in UNITED KINGDOM
Breast cancer with adjacent normal breast tissue array (2012 WHO classification), including pathology grade, TNM and clinical stage (AJCC 7th edition), 12 cases/24 cores, repalcing BR245. Breast carcinoma with adjacent normal breast tissue microarray, containing 10 cases of invasive carcinoma of no special type, 2 adjacent normal breast ...
-
Manufactured by Alphageneronbased in USA
Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form of Heat Shock Protein 70 ...
-
Manufactured by Frontier Biotechnologies Inc.based in CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. ...
-
based in USA
of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases. LB-200 has not yet advanced to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical development of LB-100 and analogs for cancer therapy, we have ...
-
Manufactured by Cellphire Therapeutics, Inc.based in USA
Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes, is an activated platelet-based hemostatic. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic ...
-
Manufactured by PolyActiva Pty Ltd.based in AUSTRALIA
Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you